Aadi Bioscience, Inc. (AADI) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Pacific Palisades, CA, 美国. 现任CEO为 David J. Lennon.
AADI 拥有 IPO日期为 2018-02-16, 53 名全职员工, 在 NASDAQ Capital Marke, 市值为 $94.89M.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
